Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
This pilot study (NCT03958097; https://www.clinicaltrials.gov/ct2/show/NCT03958097) was aimed to evaluate the efficacy and safety of PD-1 antibody combined autologous NK cells in the treatment of patients with stage IIIB/IIIC or IV non-small-cell lung cancer (NSCLC) who failed the first-line platinu...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1074906/full |
| _version_ | 1811185761263812608 |
|---|---|
| author | Lin Jia Naifei Chen Xiao Chen Chao Niu Ziling Liu Kewei Ma Nanya Wang Lei Yang Yuguang Zhao Wei Song Jin Lu Chen Chen Xiaofeng Cong Xu Wang Yinghui Xu Guozhen Cui Zengguang Liu Rongrong Chen Wei Li Jiuwei Cui |
| author_facet | Lin Jia Naifei Chen Xiao Chen Chao Niu Ziling Liu Kewei Ma Nanya Wang Lei Yang Yuguang Zhao Wei Song Jin Lu Chen Chen Xiaofeng Cong Xu Wang Yinghui Xu Guozhen Cui Zengguang Liu Rongrong Chen Wei Li Jiuwei Cui |
| author_sort | Lin Jia |
| collection | DOAJ |
| description | This pilot study (NCT03958097; https://www.clinicaltrials.gov/ct2/show/NCT03958097) was aimed to evaluate the efficacy and safety of PD-1 antibody combined autologous NK cells in the treatment of patients with stage IIIB/IIIC or IV non-small-cell lung cancer (NSCLC) who failed the first-line platinum-based chemotherapy. All patients received both sintilimab 200mg and 3×109 NK cells every 3 weeks. 20 patients were enrolled, median follow up time was 22.6 months. The median PFS was 11.6 months, ORR was 45%. Median OS was 17.7 months, 6-month OS rate and 12-month OS rate was 95.0% and 80.0%. Unexpected adverse events were not observed. 2 patients reported grade 3 adverse events (hypertriglyceridemia, neutropenia and increased creatine kinase). The autologous NK cells did not add extra adverse events to the ICI treatment. Autologous NK plus sintilimab showed promising antitumor activity and an acceptable safety profile in advanced driven-mutation negative NSCLC who failed on the first line treatment. |
| first_indexed | 2024-04-11T13:34:41Z |
| format | Article |
| id | doaj.art-c1cae90481564c44ae6b5f618df55028 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T13:34:41Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c1cae90481564c44ae6b5f618df550282022-12-22T04:21:36ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-12-011310.3389/fimmu.2022.10749061074906Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapyLin Jia0Naifei Chen1Xiao Chen2Chao Niu3Ziling Liu4Kewei Ma5Nanya Wang6Lei Yang7Yuguang Zhao8Wei Song9Jin Lu10Chen Chen11Xiaofeng Cong12Xu Wang13Yinghui Xu14Guozhen Cui15Zengguang Liu16Rongrong Chen17Wei Li18Jiuwei Cui19Cancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Medical Center, GenePlus-Beijing, Beijing, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaThis pilot study (NCT03958097; https://www.clinicaltrials.gov/ct2/show/NCT03958097) was aimed to evaluate the efficacy and safety of PD-1 antibody combined autologous NK cells in the treatment of patients with stage IIIB/IIIC or IV non-small-cell lung cancer (NSCLC) who failed the first-line platinum-based chemotherapy. All patients received both sintilimab 200mg and 3×109 NK cells every 3 weeks. 20 patients were enrolled, median follow up time was 22.6 months. The median PFS was 11.6 months, ORR was 45%. Median OS was 17.7 months, 6-month OS rate and 12-month OS rate was 95.0% and 80.0%. Unexpected adverse events were not observed. 2 patients reported grade 3 adverse events (hypertriglyceridemia, neutropenia and increased creatine kinase). The autologous NK cells did not add extra adverse events to the ICI treatment. Autologous NK plus sintilimab showed promising antitumor activity and an acceptable safety profile in advanced driven-mutation negative NSCLC who failed on the first line treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1074906/fullnon-small cell lung cancerPD1 antibodyNK cellsimmunotherapyimmune cell therapy |
| spellingShingle | Lin Jia Naifei Chen Xiao Chen Chao Niu Ziling Liu Kewei Ma Nanya Wang Lei Yang Yuguang Zhao Wei Song Jin Lu Chen Chen Xiaofeng Cong Xu Wang Yinghui Xu Guozhen Cui Zengguang Liu Rongrong Chen Wei Li Jiuwei Cui Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy Frontiers in Immunology non-small cell lung cancer PD1 antibody NK cells immunotherapy immune cell therapy |
| title | Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy |
| title_full | Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy |
| title_fullStr | Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy |
| title_full_unstemmed | Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy |
| title_short | Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy |
| title_sort | sintilimab plus autologous nk cells as second line treatment for advanced non small cell lung cancer previous treated with platinum containing chemotherapy |
| topic | non-small cell lung cancer PD1 antibody NK cells immunotherapy immune cell therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1074906/full |
| work_keys_str_mv | AT linjia sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT naifeichen sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT xiaochen sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT chaoniu sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT zilingliu sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT keweima sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT nanyawang sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT leiyang sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT yuguangzhao sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT weisong sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT jinlu sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT chenchen sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT xiaofengcong sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT xuwang sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT yinghuixu sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT guozhencui sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT zengguangliu sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT rongrongchen sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT weili sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy AT jiuweicui sintilimabplusautologousnkcellsassecondlinetreatmentforadvancednonsmallcelllungcancerprevioustreatedwithplatinumcontainingchemotherapy |